FIELD: biotechnology.
SUBSTANCE: described is a vector system based on an adeno-associated virus (AAV) for expression of a protein of an ATP-binding cassette, a subfamily A, member 4 (ABCA4) of a human in a target cell, containing a first AAV vector containing a first nucleic acid sequence and a second AAV vector containing a second nucleic acid sequence; wherein the first nucleic acid sequence comprises a 5'-terminal part of the ABCA4 coding sequence (CDS) and the second nucleic acid sequence comprises a 3'-terminal part of the ABCA4 CDS, and the 5'-terminal part and the 3'-terminal part together include the whole ABCA4 CDS; wherein the first nucleic acid sequence comprises a sequence of adjacent nucleotides corresponding to nucleotides 105-3597 SEQ ID NO: 1 or SEQ ID NO: 2; wherein the second nucleic acid sequence comprises a sequence of adjacent nucleotides corresponding to nucleotides 3806-6926 SEQ ID NO: 1 or SEQ ID NO: 2; wherein each of the first nucleic acid sequence and the second nucleic acid sequence comprises an overlap area of the sequences; and wherein the overlap area of the sequences comprises at least approximately 20 adjacent nucleotides from the nucleic acid sequence corresponding to nucleotides 3598-3805 SEQ ID NO: 1 or SEQ ID NO: 2. The present invention also relates to an application of AAV vector systems in prevention or treatment of a disease characterised by degradation of retinal cells, preferably, Stargardt disease.
EFFECT: invention expands the range of means for treating diseases characterised by degradation of retinal cells.
22 cl, 12 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
GENOTHERAPY CONSTRUCTIONS FOR TREATMENT OF WILSON'S DISEASE | 2020 |
|
RU2807158C2 |
ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2746991C2 |
MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
MODIFIED ADENO-ASSOCIATED VIRUS VECTOR COMPOSITIONS | 2013 |
|
RU2679843C2 |
ADENO-ASSOCIATED VIRAL VECTOR CONSISTING OF CAPSID PROTEINS PHP_B, NUCLEIC ACID CODING SMN PROTEIN, AND USE THEREOF | 2022 |
|
RU2833225C2 |
ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2718047C2 |
RNAi AGENT OPTION | 2018 |
|
RU2789647C2 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS AND DISEASES RELATED TO RDH12 | 2017 |
|
RU2764920C2 |
Authors
Dates
2022-02-03—Published
2017-06-14—Filed